Mark Marino

NPI: 1508386376
Total Payments
$902,273
2023 Payments
$21,856
Companies
4
Transactions
59

Payment Breakdown by Category

Consulting$881,470 (97.7%)
Research$20,803 (2.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $881,470 56 97.7%
Unspecified $20,803 3 2.3%

Payments by Type

General
$881,470
56 transactions
Research
$20,803
3 transactions

Top Paying Companies

Company Total Records Latest Year
Heron Therapeutics, Inc. $470,110 35 $0 (2022)
Adare Pharmaceuticals, Inc. $347,660 18 $0 (2020)
Antares Pharma, Inc. $63,700 3 $0 (2023)
Vyera Pharmaceuticals, LLC $20,803 3 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2023 $21,856 1 Antares Pharma, Inc. ($21,856)
2022 $65,244 4 Antares Pharma, Inc. ($41,844)
2021 $71,550 6 Heron Therapeutics, Inc. ($71,550)
2020 $199,517 16 Heron Therapeutics, Inc. ($111,600)
2019 $299,075 19 Adare Pharmaceuticals, Inc. ($213,115)
2018 $236,491 12 Heron Therapeutics, Inc. ($177,600)
2017 $8,540 1 Vyera Pharmaceuticals, LLC ($8,540)

All Payment Transactions

59 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
01/17/2023 Antares Pharma, Inc. Consulting Fee Cash or cash equivalent $21,856.25 General
11/09/2022 Antares Pharma, Inc. Consulting Fee Cash or cash equivalent $21,856.25 General
03/24/2022 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $12,900.00 General
Category: Postoperative Pain
03/03/2022 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $10,500.00 General
Category: Postoperative Pain
03/01/2022 Antares Pharma, Inc. Consulting Fee Cash or cash equivalent $19,987.50 General
10/14/2021 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $12,000.00 General
Category: Postoperative Pain
07/22/2021 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $11,400.00 General
Category: Postoperative Pain
06/03/2021 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $11,100.00 General
Category: Postoperative Pain
04/29/2021 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $7,200.00 General
Category: Postoperative Pain
04/01/2021 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $24,750.00 General
Category: Postoperative Pain
01/28/2021 Heron Therapeutics, Inc. Zynrelef (Drug) Consulting Fee Cash or cash equivalent $5,100.00 General
Category: Postoperative Pain
12/30/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $20,850.00 General
12/03/2020 Adare Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $6,200.00 General
11/19/2020 Adare Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $6,200.00 General
10/21/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $21,150.00 General
09/08/2020 Adare Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $13,800.00 General
08/18/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $11,850.00 General
08/18/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $9,000.00 General
07/27/2020 Adare Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $25,800.00 General
06/29/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $4,350.00 General
05/27/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $11,400.00 General
04/28/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $7,800.00 General
03/05/2020 Adare Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $26,264.00 General
02/27/2020 Heron Therapeutics, Inc. HTX-011 (Drug) Consulting Fee Cash or cash equivalent $8,550.00 General
02/20/2020 Adare Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $9,653.28 General

Research Studies & Clinical Trials

Study Name Company Amount Records
TUR-006 Vyera Pharmaceuticals, LLC $20,803 3

About Mark Marino

Mark Marino is a Internal Medicine healthcare provider based in Carlsbad, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2017. The National Provider Identifier (NPI) number assigned to this provider is 1508386376.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Marino has received a total of $902,273 in payments from pharmaceutical and medical device companies, with $21,856 received in 2023. These payments were reported across 59 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($881,470).

Practice Information

  • Specialty Internal Medicine
  • Other Specialties Internal Medicine
  • Location Carlsbad, CA
  • Active Since 06/22/2017
  • Last Updated 07/21/2022
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1508386376

Products in Payments

  • HTX-011 (Drug) $375,160
  • Zynrelef (Drug) $94,950

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in Carlsbad